Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2020 1
2021 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

3 results
Results by year
Filters applied: . Clear all
Page 1
CD30 and ALK combination therapy has high therapeutic potency in RANBP2-ALK-rearranged epithelioid inflammatory myofibroblastic sarcoma.
Fordham AM, Xie J, Gifford AJ, Wadham C, Morgan LT, Mould EVA, Fadia M, Zhai L, Massudi H, Ali ZS, Marshall GM, Lukeis RE, Fletcher JI, MacKenzie KL, Trahair TN. Fordham AM, et al. Br J Cancer. 2020 Sep;123(7):1101-1113. doi: 10.1038/s41416-020-0996-2. Epub 2020 Jul 20. Br J Cancer. 2020. PMID: 32684628 Free PMC article.
Potentiating the cellular targeting and anti-tumor activity of Dp44mT via binding to human serum albumin: two saturable mechanisms of Dp44mT uptake by cells.
Merlot AM, Sahni S, Lane DJ, Fordham AM, Pantarat N, Hibbs DE, Richardson V, Doddareddy MR, Ong JA, Huang ML, Richardson DR, Kalinowski DS. Merlot AM, et al. Among authors: fordham am. Oncotarget. 2015 Apr 30;6(12):10374-98. doi: 10.18632/oncotarget.3606. Oncotarget. 2015. PMID: 25848850 Free PMC article.